找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: New Therapies in Advanced Cutaneous Malignancies; Piotr Rutkowski,Mario Mandalà Book 2021 The Editor(s) (if applicable) and The Author(s),

[復(fù)制鏈接]
樓主: Mosquito
11#
發(fā)表于 2025-3-23 11:10:46 | 只看該作者
12#
發(fā)表于 2025-3-23 14:31:09 | 只看該作者
13#
發(fā)表于 2025-3-23 22:05:05 | 只看該作者
Dabrafenib and Trametinibta confirming significant improvement in overall survival and progression-free survival over vemurafenib therapy or dabrafenib alone. The next indication in melanoma for the combination of these drugs is adjuvant therapy, which was approved on the basis of long-term outcomes of study resulting in a
14#
發(fā)表于 2025-3-23 22:42:31 | 只看該作者
15#
發(fā)表于 2025-3-24 05:57:51 | 只看該作者
16#
發(fā)表于 2025-3-24 09:26:20 | 只看該作者
Vismodegib and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
17#
發(fā)表于 2025-3-24 12:34:50 | 只看該作者
18#
發(fā)表于 2025-3-24 17:57:34 | 只看該作者
19#
發(fā)表于 2025-3-24 21:10:37 | 只看該作者
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectivesand adjuvant treatment of melanoma. The first checkpoint inhibitor to be approved by FDA and EMA for treatment of melanoma was ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, based on proven benefit in terms of overall survival and recurrence-free survival in advanced and ear
20#
發(fā)表于 2025-3-25 00:41:36 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 03:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
彰武县| 滦平县| 湖口县| 临清市| 颍上县| 阿坝县| 乐都县| 南乐县| 上杭县| 平罗县| 普陀区| 从江县| 黑龙江省| 崇信县| 鞍山市| 韶关市| 梧州市| 大竹县| 巴林左旗| 龙口市| 黔江区| 甘孜县| 峨眉山市| 容城县| 盘锦市| 湘西| 大洼县| 新和县| 县级市| 怀来县| 英吉沙县| 阿巴嘎旗| 崇明县| 崇文区| 鄯善县| 淅川县| 广饶县| 玉田县| 阳高县| 常宁市| 宁陵县|